Skip to main content

Advertisement

SpringerLink
Log in

Adherence with Medications Used to Treat Osteoporosis: Behavioral Insights

  • Current Therapeutics (SL Silverman, Section Editor)
  • Published:
Current Osteoporosis Reports Aims and scope Submit manuscript

Abstract

Non-persistence (never starting or stopping medication prematurely) and non-compliance (taking medication inappropriately) with fracture prevention medication among those at high risk of fracture remain significant barriers to optimal reduction of osteoporotic fractures. Current research suggest that for patients to persist and comply with prescriptions for fracture prevention medication, they need to believe that they are at significant risk of fracture, that the prescribed medication can safely reduce their risk of fracture without exposing them to long-term harm, that equally effective non-medicinal therapies are not available, and that they can successfully execute medication use in the context of their daily task demands. Further research is needed to understand; a) the mental models of osteoporosis, fractures, and medications used to treat osteoporosis that patients employ when making decisions as to whether or not to take fracture prevention medication; and b) how patients arbitrage information from various sources (health care providers, family, friends, and other sources) to formulate their beliefs about osteoporosis and medications used to treat it.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. • Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15(9):728–40. This descriptive study shows how medication use behavior to prevent futrue adverse health events is similar across numerous medications and target diseases.

  2. World Health Organization. Adherence to long-term therapies: Evidence for action 2003. 2003.

  3. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44–7.

    Article  PubMed  Google Scholar 

  4. Shah NR, Hirsch AG, Zacker C, Taylor S, Wood GC, Stewart WF. Factors associated with first-fill adherence rates for diabetic medications: a cohort study. J Gen Intern Med. 2009;24(2):233–7.

    Article  PubMed  Google Scholar 

  5. Shah NR, Hirsch AG, Zacker C, Wood GC, Schoenthaler A, Ogedegbe G, et al. Predictors of firstfill adherence for patients with hypertension. Am J Hypertens. 2009;22(4):392–6.

    Article  PubMed  Google Scholar 

  6. • Fischer MA, Stedman MR, Lii J, Vogeli C, Shrank WH, Brookhart MA, et al. Primary medication non-adherence: analysis of 195,930 electronic prescriptions. J Gen Intern Med. 2010;25(4):284–90. This important study is the largest of the few showing the extent and importance of primary non-adherence to a variety of medications.

    Article  PubMed  Google Scholar 

  7. Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc. 2007;82(12):1493–501.

    Article  PubMed  Google Scholar 

  8. Burden AM, Paterson JM, Solomon DH, Mamdani M, Juurlink DN, Cadarette SM. Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada. Osteoporos Int. 2012;23(3):1075–82.

    Article  PubMed  CAS  Google Scholar 

  9. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc. 2005;80(7):856–61.

    Google Scholar 

  10. Ettinger MP, Gallagher R, MacCosbe PE. Medication persistence with weekly versus daily doses of orally administered bisphosphonates. Endocr Pract. 2006;12(5):522–8.

    PubMed  Google Scholar 

  11. Weiss TW, Henderson SC, McHorney CA, Cramer JA. Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills. Curr Med Res Opin. 2007;23(9):2193–203.

    Article  PubMed  Google Scholar 

  12. Rossini M, Viapiana O, Gatti D, Adami S. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review. Clin Ther. 2009;31(7):1497–510.

    Article  PubMed  CAS  Google Scholar 

  13. Hadji P, Ziller V, Gamerdinger D, Spieler W, Articus K, Baier M, et al. Quality of life and health status with zoledronic acid and generic alendronate–a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass. Osteoporos Int. 2012;23(7):2043–51.

    Article  PubMed  CAS  Google Scholar 

  14. Lee Y-K, Nho J-H, Ha Y-C, Koo K-H. Persistence with intravenous zoledronate in elderly patients with osteoporosis. Osteoporos Int. 2012;23(9):2329–33.

    Article  PubMed  CAS  Google Scholar 

  15. Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, et al. Compliance with osteoporosis medications. Arch Intern Med. 2005;165(20):2414–9.

    Article  PubMed  Google Scholar 

  16. Lo JC, Pressman AR, Omar MA, Ettinger B. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int. 2006;17(6):922–8.

    Article  PubMed  CAS  Google Scholar 

  17. Downey TW, Foltz SH, Boccuzzi SJ, Omar MA, Kahler KH. Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J. 2006;99(6):570–5.

    Article  PubMed  Google Scholar 

  18. Carr AJ, Thompson PW, Cooper C. Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos Int. 2006;17(11):1638–44.

    Article  PubMed  CAS  Google Scholar 

  19. Landfeldt E, Strom O, Robbins S, Borgstrom F. Adherence to treatment of primary osteoporosis and its association to fractures–the Swedish Adherence Register Analysis (SARA). Osteoporos Int. 2012;23(2):433–43. An important study showing the temporal relationship between non-persistence with fracture prevention medications and incident fractures, using a comprehensive national database.

    Article  PubMed  CAS  Google Scholar 

  20. Devine J, Trice S, Finney Z, Yarger S, Nwokeji E, Linton A, et al. A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System. Osteoporos Int. 2012;23(4):1415–24.

    Article  PubMed  CAS  Google Scholar 

  21. Wamala S, Merlo J, Bostrom G, Hogstedt C, Agren G. Socioeconomic disadvantage and primary non-adherence with medication in Sweden. Int J Qual Health Care. 2007;19(3):134–40.

    Article  PubMed  Google Scholar 

  22. Papaioannou A, Ioannidis G, Adachi JD, Sebaldt RJ, Ferko N, Puglia M, et al. Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int. 2003;14(10):808–13.

    Article  PubMed  CAS  Google Scholar 

  23. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 2004;48(3):271–87.

    Article  PubMed  CAS  Google Scholar 

  24. Zambon A, Baio G, Mazzaglia G, Merlino L, Corrao G. Discontinuity and failures of therapy with bisphosphonates: joint assessment of predictors with multi-state models. Pharmacoepidemiol Drug Saf. 2008;17(3):260–9.

    Article  PubMed  CAS  Google Scholar 

  25. Pressman A, Forsyth B, Ettinger B, Tosteson AN. Initiation of osteoporosis treatment after bone mineral density testing. Osteoporos Int. 2001;12(5):337–42.

    Article  PubMed  CAS  Google Scholar 

  26. Solomon DH, Levin E, Helfgott SM. Patterns of medication use before and after bone densitometry: factors associated with appropriate treatment. J Rheumatol. 2000;27(6):1496–500.

    PubMed  CAS  Google Scholar 

  27. Rubin SM, Cummings SR. Results of bone densitometry affect women's decisions about taking measures to prevent fractures. Ann Intern Med. 1992;116(12 Pt 1):990–5.

    PubMed  CAS  Google Scholar 

  28. Silverman SL, Greenwald M, Klein RA, Drinkwater BL. Effect of bone density information on decisions about hormone replacement therapy: a randomized trial. Obstet Gynecol. 1997;89(3):321–5.

    Article  PubMed  CAS  Google Scholar 

  29. Pickney CS, Arnason JA. Correlation between patient recall of bone densitometry results and subsequent treatment adherence. Osteoporos Int. 2005;16(9):1156–60.

    Article  PubMed  Google Scholar 

  30. Berecki-Gisolf J, Hockey R, Dobson A. Adherence to bisphosphonate treatment by elderly women. Menopause. 2008;15(5):984–90.

    Article  PubMed  Google Scholar 

  31. Penning-van Beest FJ, Erkens JA, Olson M, Herings RM. Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. Curr Med Res Opin. 2008;24(5):1337–44.

    Article  PubMed  CAS  Google Scholar 

  32. Gould ON, McDonald-Miszcak L, King B. Metacognition and medication adherence: how do older adults remember? Exp Aging Res. 1997;23:315–42.

    Article  PubMed  CAS  Google Scholar 

  33. Rosen MI, Beauvais JE, Rigsby MO, Salahi JT, Ryan CE, Cramer JA. Neuropsychological correlates of suboptimal adherence to metformin. J Behav Med. 2003;26(4):349–60.

    Article  PubMed  Google Scholar 

  34. Gray SL, Mahoney JE, Blough DK. Medication adherence in elderly patients receiving home health services following hospital discharge. Ann Pharmacother. 2001;35(5):539–45.

    Article  PubMed  CAS  Google Scholar 

  35. Salas M, In't Veld BA, van der Linden PD, Hofman A, Breteler M, Stricker BH. Impaired cognitive function and compliance with antihypertensive drugs in elderly: the Rotterdam Study. Clin Pharmacol Ther. 2001;70(6):561–6.

    Article  PubMed  CAS  Google Scholar 

  36. Kiortsis DN, Giral P, Bruckert E, Turpin G. Factors associated with low compliance with lipidlowering drugs in hyperlipidemic patients. J Clin Pharm Ther. 2000;25(6):445–51.

    Article  PubMed  CAS  Google Scholar 

  37. Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E. A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health. 2011;14(4):571–81.

    Article  PubMed  Google Scholar 

  38. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81(8):1013–22.

    Article  PubMed  Google Scholar 

  39. • Patrick AR, Brookhart MA, Losina E, Schousboe JT, Cadarette SM, Mogun H, et al. The complex relation between bisphosphonate adherence and fracture reduction. J Clin Endocrinol Metab. 2010;95(7):3251–9. The most detailed study to date exploring the details of the relationship between level and adherence to fracture prevention medication and incident fractures.

  40. Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F, Vannecke C, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int. 2008;19(6):811–8.

    Article  PubMed  CAS  Google Scholar 

  41. Sheehy O, Kindundu C, Barbeau M, LeLorier J. Adherence to weekly oral bisphosphonate therapy: cost of wasted drugs and fractures. Osteoporos Int. 2009;20(9):1583–94.

    Article  PubMed  CAS  Google Scholar 

  42. Halpern R, Becker L, Iqbal SU, Kazis LE, Macarios D, Badamgarav E. The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis. J Manag Care Pharm. 2011;17(1):25–39.

    PubMed  Google Scholar 

  43. Sunyecz JA, Mucha L, Baser O, Barr CE, Amonkar MM. Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization. Osteoporos Int. 2008;19(10):1421–9.

    Article  PubMed  CAS  Google Scholar 

  44. Cadarette SM, Solomon DH, Katz JN, Patrick AR, Brookhart MA. Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors. Osteoporos Int. 2011;22(3):943–54.

    Article  PubMed  CAS  Google Scholar 

  45. Curtis JR, Larson JC, Delzell E, Brookhart MA, Cadarette SM, Chlebowski R, et al. Placebo adherence, clinical outcomes, and mortality in the women's health initiative randomized hormone therapy trials. Med Care. 2011;49(5):427–35.

    Article  PubMed  Google Scholar 

  46. Curtis JR, Delzell E, Chen L, Black D, Ensrud K, Judd S, et al. The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial. J Bone Miner Res. 2011;26(4):683–8.

    Article  PubMed  CAS  Google Scholar 

  47. Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, et al. Early discontinuation of treatment for osteoporosis. Am J Med. 2003;115(3):209–16.

    Article  PubMed  Google Scholar 

  48. Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int. 2003;14(3):259–62.

    PubMed  CAS  Google Scholar 

  49. Rossini M, Bianchi G, Di Munno O, Giannini S, Minisola S, Sinigaglia L, et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int. 2006;17(6):914–21.

    Article  PubMed  CAS  Google Scholar 

  50. Britten N, Ukoumunne OC, Boulton MG. Patients' attitudes to medicines and expectations for prescriptions. Health Expect. 2002;5(3):256–69.

    Article  PubMed  Google Scholar 

  51. Unson CG, Siccion E, Gaztambide J, Gaztambide S, Mahoney Trella P, Prestwood K. Nonadherence and osteoporosis treatment preferences of older women: a qualitative study. J Womens Health (Larchmt). 2003;12(10):1037–45.

    Article  CAS  Google Scholar 

  52. Britten N. Patients' ideas about medicines: a qualitative study in a general practice population. Br J Gen Pract. 1994;44(387):465–8.

    PubMed  CAS  Google Scholar 

  53. Lin EH, Von Korff M, Ludman EJ, Rutter C, Bush TM, Simon GE, et al. Enhancing adherence to prevent depression relapse in primary care. Gen Hosp Psychiatry. 2003;25(5):303–10.

    Article  PubMed  Google Scholar 

  54. Benson J, Britten N. Patients' decisions about whether or not to take antihypertensive drugs: qualitative study. BMJ. 2002;325(7369):873.

    Article  PubMed  Google Scholar 

  55. Horne R, Weinman J, Hankins M. The Beliefs about Medications Questionnaire: the development of a new method for assessing the cognitive representation about medication. Psychol Health. 1999;14:1–24.

    Article  Google Scholar 

  56. Donovan JL, Blake DR. Patient non-compliance: deviance or reasoned decision-making? Soc Sci Med. 1992;34(5):507–13.

    Article  PubMed  CAS  Google Scholar 

  57. Conrad P. The meaning of medications: another look at compliance. Soc Sci Med. 1985;20(1):29–37.

    Article  PubMed  CAS  Google Scholar 

  58. Shoemaker SJ, de Oliveira DR, Alves M, Ekstrand M. The medication experience: Preliminary evidence of its value for patient education and counseling on chronic medications. Patient Educ Couns. 2011;83(3):443–50.

    Article  PubMed  Google Scholar 

  59. Adams S, Pill R, Jones A. Medication, chronic illness and identity: the perspective of people with asthma. Soc Sci Med. 1997;45(2):189–201.

    Article  PubMed  CAS  Google Scholar 

  60. Dowell J, Hudson H. A qualitative study of medication-taking behaviour in primary care. Fam Pract. 1997;14(5):369–75.

    Article  PubMed  CAS  Google Scholar 

  61. • Sale JEM, Gignac MA, Hawker G, Frankel L, Beaton D, Bogoch E, et al. Decision to take osteoporosis medication in patients who have had a fracture and are 'high' risk for future fracture: a qualitative study. BMC Musculoskelet Disord. 2011;12:92. An important detailed descriptive study of how patients decide whether or not to accept a recommended prescription for fracture prevention medication.

    Article  PubMed  Google Scholar 

  62. Janz N, Becker M. The health belief model: a decade later. Heal Educ Q. 1984;11(1):1–47.

    Article  CAS  Google Scholar 

  63. Connor M, Sparks P. The theory of planned behavior and health behaviors. In: Connor M, Norman P, editors. Predicting health behavior. Philadelphia: Open University Press; 1995. p. 121–62.

    Google Scholar 

  64. Leventhal H, Diefenbach M, Leventhal EA. Illness cognition: using common sense to understand treatment adherence and affect cognitive interactions. Cogn Ther Res. 1992;16(2):143–63.

    Article  Google Scholar 

  65. Bandura A. Social foundations of thought and action. A social cognitive theory. Englewood Cliffs: Prentice-Hall, Inc.; 1986.

    Google Scholar 

  66. Buglar ME, White KM, Robinson NG. The role of self-efficacy in dental patients' brushing and flossing: testing an extended Health Belief Model. Patient Educ Couns. 2010;78(2):269–72.

    Article  PubMed  Google Scholar 

  67. Bylund CL, Galvin KM, Dunet DO, Reyes M. Using the extended health belief model to understand siblings' perceptions of risk for hereditary hemochromatosis. Patient Educ Couns. 2011;82(1):36–41.

    Article  PubMed  Google Scholar 

  68. Gillibrand R, Stevenson J. The extended health belief model applied to the experience of diabetes in young people. Br J Health Psychol. 2006;11(Pt 1):155–69.

    Article  PubMed  Google Scholar 

  69. Cline RR, Farley JF, Hansen RA, Schommer JC. Osteoporosis beliefs and antiresorptive medication use. Maturitas. 2005;50(3):196–208.

    Article  PubMed  Google Scholar 

  70. McHorney CA, Schousboe JT, Cline RR, Weiss TW. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. Curr Med Res Opin. 2007;23(12):3137–52.

    Article  PubMed  CAS  Google Scholar 

  71. Yood RA, Mazor KM, Andrade SE, Emani S, Chan W, Kahler KH. Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs. J Gen Intern Med. 2008;23(11):1815–21.

    Article  PubMed  Google Scholar 

  72. • Schousboe JT, Dowd BE, Davison ML, Kane RL. Association of medication attitudes with non-persistence and non-compliance with medication to prevent fractures. Osteoporos Int. 2010;21(11):1899–909. This study is unique in that it shows the relative importance of different medication attitudes and beliefs, included perceived self efficacy on self-reported persistence and compliance with fracture prevention medications.

  73. • Schousboe JT, Davison ML, Dowd B, Thiede Call K, Johnson P, Kane RL. Predictors of patients' perceived need for medication to prevent fracture. Med Care. 2011;49(3):273–80. This studyis unique in that it illustrates the relative importance of the quality of the patientphysician relationship and objective indicators of fracture risk, adjusted for each other, on patient perceived necessity of fracture prevention medication.

  74. Solomon DH, Brookhart MA, Tsao P, Sundaresan D, Andrade SE, Mazor K, et al. Predictors of very low adherence with medications for osteoporosis: towards development of a clinical prediction rule. Osteoporos Int. 2011;22(6):1737–43.

    Article  PubMed  CAS  Google Scholar 

  75. Bandura A. Human agency in social cognitive theory. Am Psychol. 1989;44(9):1175–84.

    Article  PubMed  CAS  Google Scholar 

  76. Resnick B, Wehren L, Orwig D. Reliability and validity of the self-efficacy and outcome expectations for osteoporosis medication adherence scales. Orthop Nurs. 2003;22(2):139–47.

    Article  PubMed  Google Scholar 

  77. Bloom G, Standing H, Lloyd R. Markets, information asymmetry and health care: towards new social contracts. Soc Sci Med. 2008;66(10):2076–87.

    Article  PubMed  Google Scholar 

  78. Thorne SE, Robinson CA. Reciprocal trust in health care relationships. J Adv Nurs. 1988;13(6):782–9.

    Article  PubMed  CAS  Google Scholar 

  79. Hall MA, Dugan E, Zheng B, Mishra AK. Trust in physicians and medical institutions: what is it, can it be measured, and does it matter? Milbank Q. 2001;79(4):613–39. v.

    Article  PubMed  CAS  Google Scholar 

  80. Goff SL, Mazor KM, Meterko V, Dodd K, Sabin J. Patients' beliefs and preferences regarding doctors' medication recommendations. J Gen Intern Med. 2008;23(3):236–41.

    Article  PubMed  Google Scholar 

  81. Buller M, Buller D. Physicians' communication style and patient satisfaction. J Heal Soc Behav. 1987;28:375–88.

    Article  CAS  Google Scholar 

  82. Charles C, Gafni A, Whelan T. Decision-making in the physician-patient encounter: revisiting the shared treatment decision-making model. Soc Sci Med. 1999;49(5):651–61.

    Article  PubMed  CAS  Google Scholar 

  83. Jahng KH, Martin LR, Golin CE, DiMatteo MR. Preferences for medical collaboration: patientphysician congruence and patient outcomes. Patient Educ Couns. 2005;57(3):308–14.

    Article  PubMed  Google Scholar 

  84. • Douglas F, Petrie KJ, Cundy T, Horne A, Gamble G, Grey A. Differing perceptions of intervention thresholds for fracture risk: a survey of patients and doctors. Osteoporos Int. 2012;23(8):2135–40. This study is an important, recent documentation of how patients and physicians perceive fracture risks and use of medications to lower those risks differently.

    Article  PubMed  CAS  Google Scholar 

  85. Cadarette SM, Carney G, Baek D, Gunraj N, Paterson JM, Dormuth CR. Osteoporosis medication prescribing in British Columbia and Ontario: impact of public drug coverage. Osteoporos Int. 2012;23(4):1475–80.

    Article  PubMed  CAS  Google Scholar 

  86. Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P. Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med. 1994;331(10):650–5.

    Article  PubMed  CAS  Google Scholar 

  87. Goldman DP, Joyce GF, Escarce JJ, Pace JE, Solomon MD, Laouri M, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291(19):2344–50.

    Article  PubMed  CAS  Google Scholar 

  88. Zafran N, Liss Z, Peled R, Sherf M, Reuveni H. Incidence and causes for failure of treatment of women with proven osteoporosis. Osteoporos Int. 2005;16(11):1375–83.

    Article  PubMed  Google Scholar 

  89. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296–310.

    Article  PubMed  CAS  Google Scholar 

  90. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990;150(9):1881–4.

    Article  PubMed  CAS  Google Scholar 

  91. Wroe AL. Intentional and unintentional nonadherence: a study of decision making. J Behav Med. 2002;25(4):355–72.

    Article  PubMed  Google Scholar 

  92. Silverman SL, Schousboe JT, Gold DT. Oral bisphosphonate compliance and persistence: a matter of choice? Osteoporos Int. 2011;22(1):21–6.

    Article  PubMed  CAS  Google Scholar 

  93. Kripalani S, Gatti ME, Jacobson TA. Association of age, health literacy, and medication management strategies with cardiovascular medication adherence. Patient Educ Couns. 2010;81(2):177–81.

    Article  PubMed  Google Scholar 

  94. Berkman ND, Sheridan SL, Donahue KE, Halpern DJ, Crotty K. Low health literacy and health outcomes: an updated systematic review. Ann Intern Med. 2011;155(2):97–107.

    PubMed  Google Scholar 

  95. Elliott RA, Shinogle JA, Peele P, Bhosle M, Hughes DA, Elliott RA, et al. Understanding medication compliance and persistence from an economics perspective. Value Health. 2008;11(4):600–10.

    Article  PubMed  Google Scholar 

  96. Roelofsma PH, van der Pligt J. On the psychology of time preference and human decisions: introduction to the special issue. Acta Psychol (Amst). 2001;108(2):91–3.

    Article  CAS  Google Scholar 

  97. Read D, Loewenstein G. Time and decision: introduction to the special issue. J Behav Decis Mak. 2000;13:141–4.

    Article  Google Scholar 

  98. Sozou PD, Seymour RM, Sozou PD, Seymour RM. Augmented discounting: interaction between ageing and time-preference behaviour. Proc R Soc London, Ser B. 2003;270(1519):1047–53.

    Article  Google Scholar 

Download references

Disclosure

The author reported no potential conflicts of interest relevant to this article.

Author information

Authors and Affiliations

  1. Park Nicollet Osteoporosis Center and Park Nicollet Institute for Research and Education, Park Nicollet Health Services, 3800 Park Nicollet Blvd., Minneapolis, MN, 55416, USA

    John T. Schousboe

  2. Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, MN, USA

    John T. Schousboe

Authors
  1. John T. Schousboe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John T. Schousboe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schousboe, J.T. Adherence with Medications Used to Treat Osteoporosis: Behavioral Insights. Curr Osteoporos Rep 11, 21–29 (2013). https://doi.org/10.1007/s11914-013-0133-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11914-013-0133-8

Keywords

Search

Navigation